Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 1/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.41 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | TDO2 | P48775 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
| ▸ | CES2 | O00748 | 1/20 | 0.40 |
| ▸ | CES1 | P23141 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21732183 | 0.93 | OPRM1 (0.42) | AOC3HDAC4HDAC7HDAC5IDO1 | |
| SCHEMBL19003606 | 0.92 | AOC3 (0.41) | AOC3HDAC4HDAC7HDAC5IDO1 | |
| SCHEMBL19002873 | 0.91 | OPRM1 (0.39) | AOC3HDAC4HDAC7HDAC5IDO1 | |
| SCHEMBL18647927 | 0.90 | OPRM1 (0.38) | AOC3 | |
| SCHEMBL7538162 | 0.89 | SLC6A2 (0.43) | AOC3HDAC4HDAC7HDAC5IDO1 | |
| SCHEMBL7538156 | 0.89 | AOC3 (0.39) | AOC3HDAC4HDAC7HDAC5IDO1 | |
| SCHEMBL21555784 | 0.85 | OPRM1 (0.39) | AOC3 | |
| SCHEMBL19101512 | 0.85 | OPRM1 (0.39) | AOC3 | |
| SCHEMBL21555772 | 0.84 | OPRM1 (0.41) | AOC3 | |
| SCHEMBL10311198 | 0.83 | AOC3 (0.45) | AOC3HDAC4HDAC7HDAC5IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200296966-A1 | VOLATILE APPLICATIONS AGAINST PATHOGENS | AGROFRESH INC (US) | 2020-09-24 | — | — | US | disclosed |
| EP-2938344-B1 | PIPERAZINE-SUBSTITUTED [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES | MERCK SHARP & DOHME (US) | 2017-06-21 | — | — | EP | disclosed |
| EP-1714961-B1 | INDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2015-12-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200296966-A1 | VOLATILE APPLICATIONS AGAINST PATHOGENS | OXA1L, VAPB, TIAL1 | AOC3 322/4885HDAC4 1669/4885HDAC7 1881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.